10 April, 2017
  •  
  •  

Is it Worth the Risk?

Continuous improvement is fundamental in a competitive market and is at the heart of everything we do…

Contract Electronics Manufacturer, Cogent Technology are pleased to announced unsurpassed audit results for the first quarter of 2017.   Zero non-conformities where detected during our ISO9001, ISO 13485, ISO 14001 Audits in March and a rigorous FDA inspection, to 21CFR820, in February 2017 which yielded an outcome of No Action Indicated (NAI).

With No Action Indicated from Cogent’s FDA Audit, moving your manufacturing to Cogent Technology ensures product quality and provides you with the confidence of having your product manufactured under a tried and tested process.   This not only eliminates risk of regulatory import stop due to the failure of your Contract Manufacturing Organisation but even if you are not exporting your product, industrial, medical or defence, you will still benefit by having full traceability of your manufacturing process and parts.

 

Aaron Cross, Quality Manager at Cogent Technology says;

Cogent’s pursuit of continuous improvement has led to a well-oiled manufacturing process capable of delivering consistently high quality devices, to the timescales our customers expect.”

Nigel Slator, Managing Director remarked;

These recent audit results are a real testament to the professionalism of the team at Cogent Technology and customers, old and new, can rest assured that their products will meet the required regulatory standards.”   One of the key drivers behind this success is the control and process discipline that is inherent within our unique MaPS system.

The system not only gives the adherence to QMS requirements that the above audits examine but a whole of business and operational planning and monitoring solution.   So to free yourself of the risk of non-compliant manufacture, speak with us to see what is setting Cogent Technology apart and feel free to visit us on stand E81.